Inhibitory Effects of Phyllanthus amarus and Its Major Lignans on Human Microsomal Cytochrome P450 Activities: Evidence for CYP3A4 Mechanism-Based Inhibition
Tóm tắt
Từ khóa
Tài liệu tham khảo
1) Zhou, S. F.: Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. <i>Curr. Drug Metab.</i>, <b>9</b>: 310–322 (2008).
2) Zhou, S. F., Xue, C. C., Yu, X. Q., Li, C. and Wang, G.: Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. <i>Ther. Drug Monit.</i>, <b>29</b>: 687–710 (2007).
3) Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M. and McLeod, H. L.: Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. <i>Clin. Pharmacokinet.</i>, <b>44</b>: 279–304 (2005).
4) Aueviriyavit, S., Kobayashi, K. and Chiba, K.: Species differences in mechanism-based inactivation of CYP3A in humans, rats and mice. <i>Drug Metab. Pharmacokinet.</i>, <b>25</b>: 93–100 (2010).
5) Dresser, G. K., Spence, J. D. and Bailey, D. G.: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. <i>Clin. Pharmacokinet.</i>, <b>38</b>: 41–57 (2000).
6) Tassaneeyakul, W., Guo, L.-Q., Fukuda, K., Ohta, T. and Yamazoe, Y.: Inhibition selectivity of grapefruit juice components on human cytochromes P450. <i>Arch. Biochem. Biophys.</i>, <b>378</b>: 356–363 (2000).
7) Iwata, H., Tezuka, Y., Kadota, S., Hiratsuka, A. and Watabe, T.: Mechanism-based inactivation of human liver microsomal CYP3A4 by rutaecarpine and limonin from Evodia fruit extract. <i>Drug Metab. Pharmacokinet.</i>, <b>20</b>: 34–45 (2005).
8) Usia, T., Watabe, T., Kadota, S. and Tezuka, Y.: Metabolite-cytochrome P450 complex formation by methylenedioxyphenyl lignans of <i>Piper cubeba</i>: mechanism-based inhibition. <i>Life Sci.</i>, <b>76</b>: 2381–2391 (2005).
9) Usia, T., Watabe, T., Kadota, S. and Tezuka, Y.: Mechanism-based inhibition of CYP3A4 by constituents of <i>Zingiber aromaticum</i>. <i>Biol. Pharm. Bull.</i>, <b>28</b>: 495–499 (2005).
10) Tassaneeyakul, W., Tassaneeyakul, W., Vannaprasaht, S. and Yamazoe, Y.: Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice. <i>Br. J. Clin. Pharmacol.</i>, <b>49</b>: 139–144 (2000).
11) Bailey, D. G., Spence, J. D., Munoz, C. and Arnold, J. M. O.: Interaction of citrus juices with felodipine and nifedipine. <i>Lancet</i>, <b>337</b>: 268–269 (1991).
12) Ducharme, M. P., Warbasse, L. H. and Edwards, D. J.: Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. <i>Clin. Pharmacol. Ther.</i>, <b>57</b>: 485–491 (1995).
13) Calixto, J. B., Santos, A. R., Cechinel Filho, V. and Yunes, R. A.: A review of the plants of the genus <i>Phyllanthus</i>: their chemistry, pharmacology, and therapeutic potential. <i>Med. Res. Rev.</i>, <b>18</b>: 225–258 (1998).
14) Kiemer, A. K., Hartung, T., Huber, C. and Vollmar, A. M.: <i>Phyllanthus amarus</i> has anti-inflammatory potential by inhibition of iNOS, COX-2, and cytokines via the NF-kappaB pathway. <i>J. Hepatol.</i>, <b>38</b>: 289–297 (2003).
15) Kassuya, C. A. L., Leite, D. F. P., de Melo, L. V., Rehder, V. L. G. and Calixto, J. B.: Anti-inflammatory properties of extracts, fractions and lignans isolated from <i>Phyllanthus amarus</i>. <i>Planta Med.</i>, <b>71</b>: 721–726 (2005).
16) Faremi, T. Y., Suru, S. M., Fafunso, M. A. and Obioha, U. E.: Hepatoprotective potentials of <i>Phyllanthus amarus</i> against ethanol-induced oxidative stress in rats. <i>Food Chem. Toxicol.</i>, <b>46</b>: 2658–2664 (2008).
17) Naaz, F., Javed, S. and Abdin, M. Z.: Hepatoprotective effect of ethanolic extract of <i>Phyllanthus amarus</i> Schum. et Thonn. on aflatoxin B1-induced liver damage in mice. <i>J. Ethnopharmacol.</i>, <b>113</b>: 503–509 (2007).
18) Notka, F., Meier, G. and Wagner, R.: Concerted inhibitory activities of <i>Phyllanthus amarus</i> on HIV replication in vitro and ex vivo. <i>Antiviral Res.</i>, <b>64</b>: 93–102 (2004).
19) Pramyothin, P., Ngamtin, C., Poungshompoo, S. and Chaichantipyuth, C.: Hepatoprotective activity of <i>Phyllanthus amarus</i> Schum. et. Thonn. extract in ethanol treated rats: in vitro and in vivo studies. <i>J. Ethnopharmacol.</i>, <b>114</b>: 169–173 (2007).
20) Krithika, R., Mohankumar, R., Verma, R. J., Shrivastav, P. S., Mohamad, I. L., Gunasekaran, P. and Narasimhan, S.: Isolation, characterization and antioxidative effect of phyllanthin against CCl<sub>4</sub>-induced toxicity in HepG2 cell line. <i>Chem. Biol. Interact.</i>, <b>181</b>: 351–358 (2009).
21) Chirdchupunseree, H. and Pramyothin, P.: Protective activity of phyllanthin in ethanol-treated primary culture of rat hepatocytes. <i>J. Ethnopharmacol.</i>, <b>128</b>: 172–176 (2010).
22) Murugaiyah, V. and Chan, K. L.: Antihyperuricemic lignans from the leaves of <i>Phyllanthus niruri</i>. <i>Planta Med.</i>, <b>72</b>: 1262–1267 (2006).
23) Appiah-Opong, R., Commandeur, J. N., Axson, C. and Vermeulen, N. P.: Interactions between cytochromes P450, glutathione <i>S</i>-transferases and Ghanaian medicinal plants. <i>Food Chem. Toxicol.</i>, <b>46</b>: 3598–3603 (2008).
24) Hari Kumar, K. B. and Kuttan, R.: Inhibition of drug metabolizing enzymes (cytochrome P450) in vitro as well as in vivo by <i>Phyllanthus amarus</i> SCHUM & THONN. <i>Biol. Pharm. Bull.</i>, <b>29</b>: 1310–1313 (2006).
25) Tassaneeyakul, W., Birkett, D. J., McManus, M. E., Veronese, M. E., Andersson, T., Tukey, R. H. and Miners, J. O.: Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. <i>Biochem. Pharmacol.</i>, <b>47</b>: 1767–1776 (1994).
26) Somanabandhu, A., Nitayangkura, S., Mahidol, C., Ruchirawat, S., Likhitwitayawuid, K., Shieh, H.-l., Chai, H., Pezzuto, J. M. and Cordell, G. A.: 1H- and 13C-NMR assignments of phyllanthin and hypophyllanthin: Lignans that enhance cytotoxic responses with cultured multidrug-resistant cells. <i>J. Nat. Prod.</i>, <b>56</b>: 233–239 (1993).
27) Guo, L. Q., Fukuda, K., Ohta, T. and Yamazoe, Y.: Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. <i>Drug Metab. Dispos.</i>, <b>28</b>: 766–771 (2000).
28) Galetin, A., Gertz, M. and Houston, J. B.: Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions. <i>Drug Metab. Pharmacokinet.</i>, <b>25</b>: 28–47 (2010).
29) Tassaneeyakul, W., Guo, L. Q., Fukuda, K., Ohta, T. and Yamazoe, Y.: Inhibition selectivity of grapefruit juice components on human cytochromes P450. <i>Arch. Biochem. Biophys.</i>, <b>378</b>: 356–363 (2000).
30) Tsunoda, S. M., Velez, R. L., von Moltke, L. L. and Greenblatt, D. J.: Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. <i>Clin. Pharmacol. Ther.</i>, <b>66</b>: 461–471 (1999).
31) Wu, C. Y., Benet, L. Z., Hebert, M. F., Gupta, S. K., Rowland, M., Gomez, D. Y. and Wacher, V. J.: Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. <i>Clin. Pharmacol. Ther.</i>, <b>58</b>: 492–497 (1995).
32) Chaudhary, A. and Willett, K. L.: Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. John's wort. <i>Toxicology</i>, <b>217</b>: 194–205 (2006).
33) Chen, Y., Xiao, P., Ou-Yang, D. S., Fan, L., Guo, D., Wang, Y. N., Han, Y., Tu, J. H., Zhou, G., Huang, Y. F. and Zhou, H. H.: Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, <i>N</i>-acetyltransferase and xanthine oxidase activity in healthy volunteers. <i>Clin. Exp. Pharmacol. Physiol.</i>, <b>36</b>: 828–833 (2009).